Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Cardiac PoC Testing Devices Market: Deep Analysis by Production Overview and Insights 2017-2025
Cardiac POC testing is a test performed for the diagnosis of heart disorders. POC or Point-of-care testing, also referred to as bedside test, is a diagnostic test at the point or position of care at the same place and time of patient care


Cardiac PoC
BriefingWire.com, 9/13/2019 - Cardiac POC testing is a test performed for the diagnosis of heart disorders. POC or Point-of-care testing, also referred to as bedside test, is a diagnostic test at the point or position of care at the same place and time of patient care. Cardiac POC testing is a simple blood test that includes cholesterol and coagulation testing. Coagulation testing helps physicians examine the risk of developing thrombosis, clotting and bleeding inside blood vessels in the body, including the heart. Cardiac POC tests include Troponin, Creatine Kinase MB Isoenzyme s, and Brain Natriuretic Peptide (BNP) analysis, which are mainly employed to identify cardiovascular ailments such as, heart failure, myocardial infarction, and coronary syndromes.

Request a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/192

Market Dynamics

The market for cardiac POC testing devices is gaining significant traction due to rising prevalence of cardiac disorders. According to World Health Organizations (WHO), 2011, around 8 million people suffered from coronary and peripheral heart diseases, which recorded the major cause of all the deaths, accounting for around 44% of total deaths in the U.S. Technological innovations and developments of cardiac POC testing devices are contributing to the market growth. For instance, the FDA approval of Firmware software in August 2017, launched by Abbott Laboratories is embedded in the hardware of a cardiac testing device. With this device, the cardiac rhythm can be easily monitored as well as control for the people at high-risk. However, lack of operating knowledge and economic instability in emerging economies are the factors restraining the market growth.

According to the FH Foundation, a patient-centered organization devoted to research and education of Familial Hypercholesterolemia (FH), 2015, 1 in 200-500 people suffered from familial hypercholesterolemia worldwide. With increasing population, this number expected to increase in the future, thereby leading to growth in demand for testing cholesterol levels in individuals. This in turn, is expected to propel the overall growth of the cardiac POC testing devices market. According to the World Health Organization 2013, around 33.5 million of the global population was estimated to have suffered from coronary artery disease, a major condition leading to heart attack.

The growing prevalence of cardiovascular ailments is expected to increase the demand for cardiac POC testing devices, in turn, driving growth of the market. Additionally, The Patient Protection and Affordable Care Act, called Obamacare, was implemented under the Hospital Readmissions Reduction Program (HRRP), by the U.S. government in 2015 to impose penalties on hospitals. According to the penalty, the government had reduced up to 1-2% in the Medicare payment per patient, for hospital readmission within 30 days. This reduces the cost for diagnosis, in turn, accelerating growth of the cardiac POC testing devices market.

Key companies covered as a part of this study include Abbott Laboratories, Siemens Healthineers, BG Medicine Inc., Roche Diagnostics, Nexus-Dx, LifeSign LLC., and Medtronic Inc. Click To Read More On Cardiac PoC Testing Devices Market

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.